Heidenreich A, Gaddipati J P, Moul J W, Srivastava S
Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
J Urol. 1998 May;159(5):1725-30. doi: 10.1097/00005392-199805000-00101.
p16 (MTS 1) and p15 (MTS 2) are negative regulators of cell cycle progression at the G1 cell cycle checkpoint and function as tumor suppressor genes (TSG). Both p15 and p16 are located on chromosome 9p21 and alterations have been demonstrated in a variety of human malignancies and human cancer cell lines. In testicular germ cell tumors (TGCT) loss of heterozygosity of 9p21 to 23 has been observed in 41% to 72% of informative cases. The aim of our study was to examine TGCT and testicular cancer cell lines for deletions and mutations of the p15 and p16 genes.
24 testicular germ cell tumors, 4 testicular cancer cell lines (TERA I, TERA II, HTE, HTH), 8 benign testicular tumors and 9 samples of normal testicular parenchyma were examined. Examinations for loss of heterozygosity (LOH) on 9p21 were performed for IFNA, D9S171, D9S126, D9S161, D9S1748 and PKY9 locus using Southern Blot analysis. Southern Blot analysis of the p16 gene to examine gross alterations was done using random primer labeled p16 cDNA. In addition all samples were examined for mutations of exons 1 to 3 of p16 and exons 1 to 2 of p15 by polymerase chain reaction (PCR) followed by single strand conformation polymorphism (SSCP) analysis on MDE-gels. All observed band shifts on SSCP were further evaluated by direct DNA sequencing techniques.
No major deletions were detected for p16 and p15. 42% of all TGCT demonstrated LOH of the IFNA locus, 16% of the D9S161 locus and 5.5% of the D9S171 locus. No LOH was seen for the D9S126 locus. 5/24 TGCT (21%) and 1 testicular cancer cell line (TERA II) demonstrated band shifts for exon 2, 8/24 TGCT (33%) and 1 testicular cancer cell line (TERA I) showed band shifts for exon 3; 4 TGCT had an allelic loss for exon 3 on SSCP. DNA sequencing analysis for exon 2 demonstrated a single base substitution (G-->A) in codon 140 resulting in an amino acid exchange (ala-->thre) in 4 cases and a single base deletion with frame shift mutation in codon 142 in 2 cases. DNA sequencing analysis for exon 3 demonstrated a polymorphism in intron 2 in all cases. For p15 no band shifts were observed for exons 1 to 2 in TGCT or testicular cancer cell lines; none of benign testicular tumors or normal control tissues demonstrated any band shifts for p15 or p16.
We demonstrated a high frequency of mutations for exon 2 in specimens of primary testicular germ cell tumors, but not in benign tumors or normal controls. We therefore believe that p16 might be involved in the pathogenesis of human TGCT. The polymorphisms described for exon 3 might be utilized for further LOH studies. The absence of mutations in p15 gene in TGCT specimens suggests that p15 might not play an important role in the pathogenesis of testicular germ cell tumors.
p16(MTS 1)和p15(MTS 2)是细胞周期G1期关卡处细胞周期进程的负调控因子,起肿瘤抑制基因(TSG)的作用。p15和p16均位于9号染色体p21区域,在多种人类恶性肿瘤及人类癌细胞系中均已证实存在改变。在睾丸生殖细胞肿瘤(TGCT)中,41%至72%的信息病例观察到9p21至23区域杂合性缺失。本研究的目的是检测TGCT及睾丸癌细胞系中p15和p16基因的缺失与突变情况。
检测了24例睾丸生殖细胞肿瘤、4种睾丸癌细胞系(TERA I、TERA II、HTE、HTH)、8例睾丸良性肿瘤及9份正常睾丸实质样本。采用Southern印迹分析,对IFNA、D9S171、D9S126、D9S161、D9S1748及PKY9位点进行9p21区域杂合性缺失(LOH)检测。使用随机引物标记的p16 cDNA对p16基因进行Southern印迹分析,以检测大片段改变。此外,通过聚合酶链反应(PCR)对所有样本检测p16基因外显子1至3及p15基因外显子1至2的突变情况,随后在MDE凝胶上进行单链构象多态性(SSCP)分析。所有在SSCP上观察到的条带迁移均通过直接DNA测序技术进一步评估。
未检测到p16和p15的大片段缺失。所有TGCT中,42%表现出IFNA位点的LOH,16%表现出D9S161位点的LOH,5.5%表现出D9S171位点的LOH。未观察到D9S126位点的LOH。5/24例TGCT(21%)及1种睾丸癌细胞系(TERA II)外显子2出现条带迁移,8/24例TGCT(33%)及1种睾丸癌细胞系(TERA I)外显子3出现条带迁移;4例TGCT在SSCP上外显子3出现等位基因缺失。外显子2的DNA测序分析显示,4例密码子140处有单个碱基替换(G→A),导致氨基酸交换(ala→thre),2例密码子142处有单个碱基缺失并伴有移码突变。外显子3的DNA测序分析显示所有病例内含子2存在多态性。对于p15,在TGCT或睾丸癌细胞系中外显子1至2未观察到条带迁移;良性睾丸肿瘤或正常对照组织中,未发现p15或p16有任何条带迁移。
我们证实在原发性睾丸生殖细胞肿瘤标本中外显子2存在高频突变,而在良性肿瘤或正常对照中未出现。因此,我们认为p16可能参与人类TGCT的发病机制。外显子3所描述的多态性可用于进一步的LOH研究。TGCT标本中p15基因未出现突变,提示p15可能在睾丸生殖细胞肿瘤发病机制中不起重要作用。